A strategy to assess the cellular activity of E3 ligase components against neo-substrates using electrophilic probes.

E3 ligase JQ1 SKP1 SOCS box family SPSB2 VHL covalent dasatinib electroporation neo-substrate targeted protein degradation (TPD)

Journal

Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030

Informations de publication

Date de publication:
20 01 2022
Historique:
received: 31 08 2020
revised: 17 06 2021
accepted: 20 08 2021
pubmed: 10 9 2021
medline: 3 3 2022
entrez: 9 9 2021
Statut: ppublish

Résumé

While there are hundreds of predicted E3 ligases, characterizing their applications for targeted protein degradation has proved challenging. Here, we report a chemical biology approach to evaluate the ability of modified recombinant E3 ligase components to support neo-substrate degradation. Bypassing the need for specific E3 ligase binders, we use maleimide-thiol chemistry for covalent functionalization followed by E3 electroporation (COFFEE) in live cells. We demonstrate that electroporated recombinant von Hippel-Lindau (VHL) protein, covalently functionalized at its ligandable cysteine with JQ1 or dasatinib, induces degradation of BRD4 or tyrosine kinases, respectively. Furthermore, by applying COFFEE to SPSB2, a Cullin-RING ligase 5 receptor, as well as to SKP1, the adaptor protein for Cullin-RING ligase 1 F box (SCF) complexes, we validate this method as a powerful approach to define the activity of previously uncharacterized ubiquitin ligase components, and provide further evidence that not only E3 ligase receptors but also adaptors can be directly hijacked for neo-substrate degradation.

Identifiants

pubmed: 34499862
pii: S2451-9456(21)00396-2
doi: 10.1016/j.chembiol.2021.08.007
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

57-66.e6

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests All authors are or were employees of Novartis Pharma AG.

Auteurs

Benika J Pinch (BJ)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: benika.pinch@novartis.com.

Dennis L Buckley (DL)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Scott Gleim (S)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Scott M Brittain (SM)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Laura Tandeske (L)

Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA.

Pier Luca D'Alessandro (PL)

Novartis Institutes for BioMedical Research, Basel, Switzerland.

Zachary J Hauseman (ZJ)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Jennifer Lipps (J)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Lei Xu (L)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Edward P Harvey (EP)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Markus Schirle (M)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Elizabeth R Sprague (ER)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

William C Forrester (WC)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: william.forrester@novartis.com.

Dustin Dovala (D)

Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA. Electronic address: dustin.dovala@novartis.com.

Lynn M McGregor (LM)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: lynn.mcgregor@novartis.com.

Claudio R Thoma (CR)

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: claudio.thoma@novartis.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH